Image source: The Motley Fool.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE)
Q3 2020 Earnings Call
Oct 27, 2020 , 5:00 p.m. ET
Operator
For further details see:
Ultragenyx Pharmaceutical Inc (RARE) Q3 2020 Earnings Call TranscriptImage source: The Motley Fool.
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE)
Q3 2020 Earnings Call
Oct 27, 2020 , 5:00 p.m. ET
Operator
For further details see:
Ultragenyx Pharmaceutical Inc (RARE) Q3 2020 Earnings Call TranscriptMarket Wire News is a media platform, the information on this page was provided by Motley Fool via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the develo...
NOVATO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Eric Crombez, M.D., the company's c...
First quarter total revenue of $109 million, Crysvita® revenue of $83 million and Dojolvi® revenue of $16 million Reaffirmed 2024 expected total revenue guidance between $500 million to $530 million, Crysvita revenue of $375 million to $400 million, and Dojolvi revenue of $75 ...